Pemphigus

• EMA approval · 2025-10-06
  EMA Authorised: Rixathon (rituximab) — Sandoz GmbH

  EMA authorised Rixathon (rituximab) by Sandoz as a biosimilar to Rituxan for several autoimmune and hematologic diseases, expanding access t…

• EMA approval · 2025-07-14
  EMA Authorised: Ruxience (rituximab) — Pfizer Europe MA EEIG

  The EMA authorised Ruxience, a rituximab biosimilar by Pfizer Europe MA EEIG, for several indications including chronic lymphocytic leukemia…